Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Weighted Average) (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Shares Outstanding (Weighted Average) data on record, last reported at $36.5 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 6.54% year-over-year to $36.5 million; the TTM value through Sep 2025 reached $36.5 million, up 6.54%, while the annual FY2024 figure was $33.3 million, 546.44% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $36.5 million in Q3 2025 per DNTH's latest filing, up from $35.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $58.8 million in Q2 2022 and bottomed at $874234.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $24.1 million, with a median of $31.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 98.51% in 2023, then surged 3534.12% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $874234.0 in 2022, then soared by 489.48% to $5.2 million in 2023, then surged by 546.44% to $33.3 million in 2024, then rose by 9.49% to $36.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $36.5 million in Q3 2025, $35.8 million in Q2 2025, and $35.8 million in Q1 2025.